SEP 22, 2017
In this interview from ASRS 2017, Dr. Alay Banker discusses findings from the multinational randomized double-masked phase 3 SAKURA trial. Sirolimus, also known as rapamycin, is a bacteria-derived immunosuppressant that has been approved since 1999 for treatment of organ transplant rejection. The study enrolled 347 patients who were randomized to 3 doses of intravitreal sirolimus [44 mcg (active control), 440 mcg or 880 mcg] administered every 2 months. Patients who were treated with 440 mcg sirolimus showed the most significant improvements in vitreous haze and had more successful tapering of oral corticosteroids. There were no significant safety concerns.
Relevant Financial Disclosures: Dr. Banker is a consultant for Santen.